Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies

22.MAY 2019 AT 18:00:00 CET

Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers
 
MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Kiadis Pharma N.V. (“Kiadis”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announced a strategic collaboration to support clinical evaluation of an innovative cell therapy product with potential to make haploidentical hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH